Document is current
Any future updates will be listed below
-
Authors
Jiang, Wen
Jaehnig, Eric J. https://orcid.org/0000-0001-9618-6011
Liao, Yuxing https://orcid.org/0000-0002-1238-2021
Shi, Zhiao
Yaron-Barir, Tomer M. https://orcid.org/0000-0001-6574-7314
Johnson, Jared L. https://orcid.org/0000-0003-1802-6527
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Zhang, Bing https://orcid.org/0000-0001-8676-2425
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24 CA271076, R01 CA245903, U01 CA271247)
Cancer Prevention and Research Institute of Texas (RP220050, RP210027)
Robert and Janice McNair Foundation
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 10 March 2025
First Online: 20 March 2025
Change Date: 30 April 2025
Change Type: Update
Change Details: In the version of the article initially published, the sentence “The research carried out in Lewis Cantley’s laboratory was supported by grant R35 CA197588. J.L.J. was supported by The Claudia Adams Barr Program for Cancer Research Award” was missing from the Acknowledgements section and has now been added to the HTML and PDF versions of the article.
Competing interests
: B.Z. received research funding from AstraZeneca and consulting fees from Inotiv. L.C.C. is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for PI3K-associated disease or disorder, and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment; is a co-founder and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. J.L.J. has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. T.M.Y.-B. is a co-founder of DeStroke. The remaining authors declare no competing interests.
